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Abstract
Chromogranin A (CgA) is regarded as a major, nonspecific neuroendocrine tumour (NET) marker. The results of CgA blood concentration,
however, may actually be influenced by various factors or coexisting pathological conditions. Among the factors causing a substantial
increase of the blood CgA concentration are: treatment with proton-pump inhibitors or H2 -receptor blockers, chronic atrophic gastritis
(type A), impaired renal function, prostate cancer and BPH, and rheumatoid arthritis with high level of RF IgM. In addition, the sort of
investigated biological material (whether it is serum or plasma) is of importance.
There are also many conditions which may have a moderate or little influence on the concentration of CgA, among them are: inflammato-
ry bowel disease (ulcerative colitis and Crohn’s disease), deteriorating liver function, untreated essential hypertension, heart failure, hy-
percortisolism, pregnancy, and, in some subjects, ingestion of a meal.
Proper assessment of the CgA results requires detailed knowledge about various factors, drugs, and pathological conditions influencing its
concentration in blood. (Pol J Endocrinol 2010; 61 (4): 384–387)
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Streszczenie
Chromogranina A (CgA, chromogranin A) jest obecnie uznana jako główny, niespecyficzny marker guzów neuroendokrynnych (NET,
neuroendocrine tumours). Liczne czynniki i stany patologiczne mogą wpływać na stężenie CgA. Wśród czynników powodujących najwięk-
szy wzrost stężenia CgA wymienić należy: leki z grupy inhibitorów pompy protonowej i antagonistów receptorów H2, zaś spośród róż-
nych patologii: przewlekłe zanikowe zapalenie błony śluzowej żołądka typu A (atrophic gastritis), postępująca niewydolność nerek, rak
i przerost prostaty. Wpływ na wynik oznaczenia CgA ma także rodzaj użytego materiału biologicznego (czy jest to surowica czy osocze)
oraz na przykład obecność czynnika reumatoidalnego (RF) w klasie IgM.
Istnieje również wiele czynników i stanów patologicznych, które mają umiarkowany lub niewielki wpływ na stężenie CgA, wśród nich
wymienia się: choroby zapalne jelit (wrzodziejące zapalenie jelita grubego, choroba Leśniowskiego-Crohna), niewydolność wątroby, nie-
wydolność serca, nieleczone nadciśnienie tętnicze, hiperkortyzolemia, ciąża oraz, u niektórych pacjentów, wcześniejsze spożycie posiłku.
Dla prawidłowej interpretacji oznaczeń CgA niezbędna jest dobra znajomość potencjalnego wpływu na jej stężenie we krwi różnych
czynników, stosowanych leków lub współistniejących schorzeń. (Endokrynol Pol 2010; 61 (4): 384–387)
Słowa kluczowe: chromogranina A, guzy neuroendokrynne
Introduction
Chromogranin A (CgA) is a 49-kDa hydrophilic glycopro-
tein composed of 439 aa. It is present in all normal and ab-
normal neuroendocrine cells [1, 2]. The CgA gene is located
on the 14th chromosome. CgA is a major Ca²+ storage pro-
tein and can aggregate at high concentrations of calcium
[3]. Chromogranin A belongs to the chromogranin/secre-
togranin family — acid secretory proteins which are pre-
sented in the DES (diffuse endocrine system) in the gas-
trointestinal tract, respiratory system, and endocrine glands
(adrenals, pituitary) and groups of endocrine cells in the
glandular tissues such as pancreas and thyroid [4].
The exact role and function of CgA is still unknown.
It is suggested that it could exert some intracellular and
extracellular functions:
— CgA as a pro-hormone is a precursor of biologically
active peptides (vasostatin, pancreastatin, chromo-
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statin) which have autocrine, paracrine, and endo-
crine functions;
—  It plays a role in the production, storage, transport,
and regulatory functions of peptide hormones [5-7].
CgA — circulating tumour marker
Chromogranin A is a major, nonspecific NET marker.
The expression of CgA depends on the cell type and on
the number of secretory granules present in the cells
[8]. Chromogranin A is physiologically released by exo-
cytosis and may be detected in blood as a circulating
tumour marker. CgA is a universal marker of neuroen-
docrine tissues and tumours, such as: GEP NET (gastro-
entero-pancreatic neuroendocrine tumours), carcinoid,
pheochromocytoma, thyroid medullary carcinoma, par-
athyroid adenoma, MEN 1 syndrome, neuroblastoma,
small cell lung cancer, bronchopulmonary NETs, and
others [9, 10]. Measurement of CgA levels in blood can
also be used for monitoring the progression or regres-
sion of neuroendocrine tumors during treatment.
The sensitivity of this tumour marker in NETs fluc-
tuates between 10 and 100% and its specificity between
68 and 100% [10]. In patients with metastatic disease,
CgA has a sensitivity of 60–100% and its level may in-
crease even 100–1000 times. The highest values are ob-
served in carcinoid tumours with liver metastases [11].
In small tumours (except gastrinoma) such as: insuli-
noma, paraganglioma, small bronchi carcinoids, and
pituitary tumours, the levels of CgA may be in the nor-
mal range. [12]. The highest sensitivity of CgA measure-
ment was noted in gastrinoma (100%), pheochromocy-
toma (89%), carcinoid tumours (80%), non-functioning
tumours of the endocrine pancreas (69%), and medul-
lary thyroid carcinoma (50%) [13], and usually the CgA
blood level depends on the size of the tumour and the
presence of metastasis [14, 15].
The effect of various pathological conditions
or diseases on CgA blood levels
The most common unrecognised cause of increased
CgA levels is probably silent atrophic gastritis and gas-
tritis due to Helicobacter pylori infection [16, 17].
Chronic elevation of serum gastrin levels in patients
with gastritis, especially those treated with proton pump
inhibitors, may initiate hyperplasia of the ECL of the
stomach. Therefore, measurement of serum CgA could
be a useful tool for monitoring ECL cell hyperplasia,
which potentially might precede NE cell neoplasia [18–
–20]. Patients with Helicobacter pylori—positive serolo-
gy—have higher serum gastrin and CgA levels than
those with negative serology [21]. In organ dysfunction
such as renal and liver failure, the CgA levels in serum
or plasma may also be markedly increased. In renal in-
sufficiency, the concentration of CgA may increase sys-
tematically, and the highest levels are found in end-
stage renal disease [22].
High CgA blood concentrations may also be present
in prostate carcinoma and benign prostate hypertrophy
(BPH). Plasma CgA levels in prostate cancer increase
with the severity of the disease and are associated with
a poor survival prognosis [23].
Slightly increased concentrations of CgA have been
observed in: ulcerative colitis and Crohn’s disease, Par-
kinson’s disease, rheumatoid arthritis, hyperparathy-
roidism (HPT), hyperthyroidism, in some postmeno-
pausal women (probably due to the increased sympa-
thetic tone), and during pregnancy [17, 24–25].
Severe heart diseases like infarction, heart failure and
hypertension associated with an increased sympathet-
ic tone and/or increased secretion of glucocorticoids may
also result in elevation of CgA levels [26–28].
The concentration of CgA may be also increased in
some patients with: breast cancer, lung cancer, gas-
trointestinal cancer, uterine cancer, genitourinary can-
cer, haematological cancer, and head and neck cancer,
which are generally not regarded as neuroendocrine
tumours [29].
The effect of drugs on the CgA blood level
There are two main groups of drugs: proton pump in-
hibitors (PPIs) and histamine H2-receptor blockers (H2-
-RAs), which can markedly influence the CgA blood
concentration. These drugs are very important in the
treatment of the gastro-oesophageal reflux disease, pep-
tic ulcer, and they are widely used for gastric protec-
tion during administration of steroids or nonsteroidal
anti-inflammatory drugs [30–31].
Inhibition of gastric acid secretion stimulates G cells
to produce gastrin. Therefore, long-term treatment with
proton pump inhibitors and, to a lesser extent with his-
tamine 2-receptor antagonist, may lead to the develop-
ment of gastric enterochromaffin-like (ECL) cell hyper-
plasia [32].
Regarding this very potent effect of PPI on CgA lev-
el, administration of this drug, if possible, should be
interrupted, leaving a clearance of at least three half-
lives, prior to blood sampling (it means in practice
around two weeks), or PPI should be temporarily re-
placed by a H2-blocker for two weeks and the later drug
should be discontinued three days before determina-
tion of the CgA concentration [21, 33–36].
Treatment with corticosteroids may increase the
concentration of CgA by about two times, while most
drugs used in the treatment of hypertension have little
or no effect on plasma CgA concentration [13].
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Table I. The effect of various pathological conditions and drugs on the CgA blood level
Tabela I. Wpływ różnych stanów patologicznych i leków na stężenie CgA we krwi
High or moderate increase of the blood CgA level Moderate or little increase of the blood CgA level
— proton-pump inhibitors — inflammatory bowel disease (ulcerative colitis
— histamine H2 receptor-blockers andCrohn’s disease)
— chronic atrophic gastritis (type A) — untreated essential hypertension
— impaired renal function; — acute coronary syndrome
— RF IgM — cardiac insufficiency
— some chemiotherapeutic drugs causing nephrotoxic — giant cell arteritis
effect or renal failure — deteriorating liver function (cirrhosis, chronic
— prostate cancer and BPH hepatitis)
— pancreatic adenocarcinoma
— irritable bowel syndrome
— hepatocellular carcinoma
— hyperthyroidism
— hyperparathyroidism (HPT)
— airway obstruction in smokers
— systemic rheumatoid arthritis
— Parkinson disease
— pregnancy
— non-endocrine tumours (breast cancer lung cancer,
gastrointestinal cancer, uterine cancer, genitourinary
cancer, haematological cancer, head and neck cancer)
During chemotherapy of NE tumours (e.g. with the
use of streptozotocin), the levels of CgA may increase
even if the tumour mass shrinks, which may be due to
the release of CgA from the damaged tissue or due to
the nephrotoxic effect of such drugs [37].
Some other in vivo and in vitro factors
having a potential influence on the
measurement of CgA blood level
CgA is a relatively stable protein. Biological material (se-
rum, plasma) can be stored at –20oC for a long time.
Few cycles of thawing and refreezing of samples does
not damage the molecule [38]. Circulating CgA is
present in healthy subjects, and the values obtained are
not dependent on age and sex [39,40]; only Tsao et al.
have described higher concentrations of CgA in males
than in females, regardless of age [41]. Daily fluctua-
tions of CgA can be approximately 20–25% [42], and
the higher levels are observed in the late afternoon and
at night [43]. The increase of CgA concentration after
exercise is small; it can be seen mainly in patients with
essential hypertension [44].
Considering the stability of CgA, it should be remem-
bered, however, that it can aggregate at high concen-
trations of free Ca2+ ions. For this reason, significant
differences in the CgA results may be observed depend-
ing on the sort of studied biological material, whether it
is serum or plasma. We were able to show that CgA lev-
els, measured either by IRMA or ELISA CIS-kits, appeared
to be 20–76% higher in plasma than in serum [45].
The CgA levels may be also influenced by ingestion
of a meal. A meal can stimulate G and ECL cells of the
stomach and cause the release of gastrin and CgA [46].
Such an effect was observed especially in patients who
were on long-term treatment with proton pump inhib-
itors (PPIs) or H2-RAs. So far, it is not known whether
an increase of CgA after meal may also be significant in
patients who are not treated with PPIs. For this reason,
in all the investigated patients, perhaps blood should
be collected in a fasting state [47]. Our preliminary study
on a group of healthy subjects and patients has shown
that this increase was very small, but in a few cases the
difference was about 24–36%.
Some disturbances in the determination of CgA lev-
els in serum or plasma may also be caused by: haemoly-
sis, lipaemia, turbidity of sample, presence of fibrin, and
the so-called “effect of imposing” connected with the
presence in patients samples of different (auto)antibodies
such a: heterofile-Ab, avidine-Ab, or RF-IgM [48].
Conclusions
Biochemical measurements are very important for prop-
er diagnosis, follow up, and for monitoring the effec-
tiveness of the applied treatment. Correct interpreta-
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tion of the obtained results requires good knowledge
of the analytical factors and associated diseases or patho-
logical conditions which may potentially influence the
results of laboratory determinations. In our article we
present some updated data on chromogranin A and put
special attention to the most important in vivo and in
vitro factors which have, or may have, an influence on
the measured concentration of CgA (Table I). Discus-
sion of these issues seems important for clinical prac-
tice and the proper assessment of obtained CgA results.
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